 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (November 2021) |
 | |
| Company type | Public |
|---|---|
| |
| Founded | September 5, 1998 (as BioPort Inc.) |
| Founder | Fuad El-Hibri |
| Headquarters | Gaithersburg, Maryland, U.S. |
Key people |
|
| Revenue |  US$1.05 billion (2023) |
| US$−726 million (2023) | |
| US$−761 million (2023) | |
| Total assets | US$1.82 billion (2023) |
| Total equity | US$649 million (2023) |
Number of employees | 1,600 (2023) |
| Website | emergentbiosolutions |
| Footnotes / references [1] | |
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.[2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax (Anthrax Vaccine Adsorbed),[3] the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.
- ^ "2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. March 8, 2024. Retrieved June 28, 2024.
- ^ Claybaugh, Jeff (August 30, 2018). "Gaithersburg company buys Narcan maker". WTOP News Radio. Washington, DC: Hubbard Radio. Retrieved March 27, 2019.
- ^ Hamby, Chris; Stolberg, Sheryl Gay (March 6, 2021). "How One Firm Put an 'Extraordinary Burden' on the U.S.'s Troubled Stockpile". The New York Times. Retrieved January 15, 2022.